@FierceMedDev: Water Street plans to grow a German specialty Dx company into a major player, through investment and M&A. ICYMI from FierceDiagnostics | Follow @FierceMedDev
@VarunSaxena2: It's official: Alere is spinning off its diagnostics biz. More | Follow @VarunSaxena2
@MichaelGFierce: From Harvard Research: Herpes-loaded stem cells used to kill brain tumors. More | Follow @MichaelGFierce
@EmilyWFierce: Gelesis brought in $12M for superabsorbent hydrogel technology that swells in the stomach to treat obesity. More from MedCityNews | Follow @EmilyWFierce
> FDA will hold a public workshop on 3-D printing on October 8 and 9. The Federal Register
> Dukal Corporation signed a 3-year agreement with Champs Group Purchasing to offer Champ's member with contract pricing on wound care patient products. Release
Biotech News
@FierceBiotech: Why did Pfizer's big fiesta for palbociclib fizzle? Story | Follow @FierceBiotech
@JohnCFierce: Elotuzumab: Bristol-Myers nabs another 'breakthrough' cancer drug title. More | Follow @JohnCFierce
@DamianFierce: From yesterday: The redacted bit of Pfizer's letter sort of spells out their passive-aggressive strategy. Image | Follow @DamianFierce
@EmilyMFierce: Scientists can have an impact on the antibiotic crisis by engaging the public and talking to media, says Ian Lipkin. | Follow @EmilyMFierce
> AstraZeneca slaps down Pfizer's 'final' $119B takeover bid. More
> Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data. Story
> Another animal health biotech plots an IPO. Item
Pharma News
@FiercePharma: Roche unveils more plans for plant expansions in Switzerland. Story | Follow @FiercePharma
@TracyStaton: If AstraZeneca were Harry Potter, would that make Pfizer Voldemort? More | Follow @TracyStaton
@EricPFierce: China forewarns drugmakers. It's not messing around when it comes to bribery as a sales tool. More | Follow @EricPFierce
@CarlyHFierce: First, bribery. Now, China floats tax-evasion accusations against GlaxoSmithKline. News | Follow @CarlyHFierce
> How did AstraZeneca make the Pfizer bid a Harry vs. Voldemort story? More
> Emboldened by their GSK probe, Chinese officials step up pharma snooping. Story
> Valeant's $47B Allergan buyout could spawn a breakup, CEO tells investors. News
CRO News
> WuXi wraps up construction on a new biologics shop. Item
> Bayer agrees to share trial data, but not without a list of caveats. Article
> PRA amps up its biologics footprint amid industry shift. Story
> Evotec's hybrid CRO approach pays off in Q1. More
> WuXi scores more double-digit growth amid its global expansion. Report
Biotech IT News
> Venter nabs AstraZeneca's R&D IT chief for Human Longevity. News
> Bayer, Boehringer extend access to clinical trial data. Item
> NIH lays out up to $20B in IT spending over coming decade. More
> HCL Tech adds Novartis to roster of Big Pharma clients. Story
> GSK signs up to access Metabolon's bioinformatics tools. Article